Articles Published in 2012

Pfizer acquires NextWave Pharmaceuticals

Thursday, November 29, 2012 01:49 PM

Pfizer has completed its acquisition of NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

More... »


Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »


Chiltern promotes Aize Smink and Linda Christmas

Thursday, November 29, 2012 08:00 AM

Chiltern International, a global CRO, has promoted Aize Smink and Linda Christmas to executive positions, coinciding with Dr. Jim Esinhart’s appointment as CEO.

More... »

FDA approves Cometriq to treat rare type of thyroid cancer

Thursday, November 29, 2012 08:00 AM

The FDA has approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body.

More... »

New phone app charts cases of infectious diseases

Wednesday, November 28, 2012 02:53 PM

Scientists at the University of Liverpool have developed a free iPhone application, ClickClinica, to help health authorities monitor cases of major infectious diseases in response to research that highlighted one in 10 meningitis patients were not reported to the Health Protection Agency (HPA).

More... »

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »

Roche, Broad Institute to identify novel uses for failed phase II compounds

Wednesday, November 28, 2012 01:39 PM

Roche, through its Translational and Clinical Research Center, and the Broad Institute, a biomedical and genomic research center based in Cambridge, Mass., have signed a multi-year collaboration designed to identify novel indications for promising development-stage compounds using the Broad Institute's platforms of screening technologies.

More... »

Almirall’s Constella approved in Europe for IBS-C

Wednesday, November 28, 2012 12:20 PM

The European Commission has granted marketing authorization to Almirall’s Constella (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.

More... »

IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials

Wednesday, November 28, 2012 11:16 AM

IntelliCell BioSciences, a regenerative medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs, has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers, the state university of New Jersey.

More... »

Rhythm expands Series B financing to $33M with Pfizer investment

Wednesday, November 28, 2012 10:48 AM

Rhythm, a Boston-based biotechnology company developing peptide therapeutics that for metabolic diseases, has raised an additional $8 million to complete a $33 million Series B financing.

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs